VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces a collaboration with Sysmex (TYO:6869), a leader in global in vitro diagnostics, to optimize Volition's Nu.Q® NETs H3.1 assay on the Sysmex platform.